Skip to main content

Rejuran, Recognized for the technology and quality of PharmaResearch in the Arab Countries

By: Get News
Rejuran, Recognized for the technology and quality of PharmaResearch in the Arab CountriesArab Health 2023 as the center of attention, targeting new markets including the Middle East

PharmaResearch (CEO Kim Thinkyou, Kang Ki-seok) announced that the company participated in the “Arab Health 2023” expo held in Dubai, the United Arab Emirates, from January 30 to February 2, 2023.

Arab Health 2023 was the largest medical equipment exhibition in the Middle East, and saw the participation of more than 100,000 people and 4,000 companies from about 32 countries.

In this exhibition, PharmaResearch focused on product excellence, by introducing its entire aesthetic lineup, starting with REJURAN®, an original DNA-optimizing technology polynucleotide (DOT™ PN) product, as well as the botulinum toxin ReNTox, Cleviel, and REJURAN COSMETIC that are awaiting for approval.

In particular, REJURAN® received a lot of attention from the buyers from the Middle East, Asia, and Europe. Currently, sales are being strengthened in Asia and member states of the Commonwealth of Independent States (CIS). Based on this expo, the Middle East and new overseas markets are to be pursued aggressively.

REJURAN® is a medical device made from PN, a regenerative material derived from salmon, and manufactured using DOT™, a patented technology of PharmaResearch, for temporary improvement of facial wrinkles.

Since its launch in 2014, REJURAN® has become a leading skin booster in South Korea. It is currently being registered and sold in the markets of more than 30 countries, including the United States, China, and Japan.

A participant who visited the PharmaResearch booth said that “Through this exhibition, I was able to understand why PharmaResearch’s REJURAN is Korea’s leading skin booster.” The participant added, “As K-Beauty and K-Aesthetic are gaining attention and increasing in demand in the Middle East, we hope that REJURAN, recognized for its technology and product quality, can soon be launched.”

An official from PharmaResearch said, “REJURAN’s global interest and status were confirmed yet again at this exhibition.” The official added, “We will do our best to make REJURAN a leading brand in the Middle East market, which is already quickly advancing in all of the world including the Asian and CIS countries, for its excellent DOT™ PN-based technology and product capabilities.”

PharmaResearch is a regenerative medicine-based biopharmaceutical company that manufactures and sells medicines, medical devices, cosmetics, and dietary supplements. Its focus is tissue-regenerating materials—DOT™ PDRN (where PDRN refers to deoxyribonucleotides) and DOT™ PN. PharmaResearch’s main products include REJURAN®, REJUVIEL®, CONJURAN®, REJURAN® Cosmetic, and Re-An® Eye drops.

Media Contact
Company Name: Pharmaresearch
Contact Person: Seulki Kwak
Email: Send Email
Country: South Korea

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.